Return to Listing

10 result(s) for gemzar

PI Name Protocol # Title
Christopher Ryan IRB00007943 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination with Pazopanib for Refractory Soft Tissue Sarcoma
Gina Vaccaro IRB00011256 Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer
Jeremy Cetnar IRB00011845 A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-LI Antibody) Compared with A Platinum Agent (Cisplatin or Carboplatin) in Combination with either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naïve Patients Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Khaled Tolba IRB00012012 A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of Atezolizumab (ANTI−PD-L1 ANTIBODY) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy In Patients With Completely Resected STAGE IB−IIIA Non-Small Cell Lung Cancer
Jacqueline Vuky STUDY00016506 A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma
Matthew Taylor STUDY00016884 INCB 24360-207 Protocol Title: A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Eric Anderson STUDY00016890 A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma
Charles Lopez STUDY00017094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Eric Anderson STUDY00017574 A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial
Khaled Tolba STUDY00017685 CA209-816 - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080